1WM
REGN icon

1858 Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

1858 Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-314
Closed -$224K – 131
2024
Q4 		$224K Buy
+314
New +$264K 0.18% 111

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

1858 Wealth Management's REGN Position: Q1 2025 in Review

1858 Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 314 shares — an estimated $224K sold.

1858 Wealth Management first reported a position in REGN in Q4 2024 and held it in 1 quarter. The position peaked at $224K in Q4 2024. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • 1858 Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • 1858 Wealth Management sold 314 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $224K.
  • 1858 Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • 1858 Wealth Management's Regeneron Pharmaceuticals position peaked at $224K in Q4 2024.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on 1858 Wealth Management's 13F filing for Q1 2025, filed 22 Apr 2025.